alimera sciences

Alimera Sciences Inc (NASDAQ: ALIM) extended its gains Monday after the company's treatment for diabetes-related vision loss won U.S. marketing approval. Atlanta-based Alimera slated a conference call with analysts Wednesday to offer further details on the September 26 approval of its...

Less than one hour before the close yesterday, Benzinga heard positive rumors that the NDA for ILUVIEN, which was resubmitted roughly two weeks ago, had been accepted by the Food and Drug Administration. The drug, which is a joint venture between pSivida (NASDAQ: PSDV) and Alimera Sciences (...

Citi is out with its report today on Alimera Sciences (NASDAQ: ALIM), maintaining Buy, with a $12 PT. In its note to clients, Citi writes, "On Thursday (2/3) after the close, ALIM presented 36-month followup data from its FAME trial studying Iluvien for DME (diabetic macular edema). This data is...

Oppenheimer has published a research report on Alimera Sciences (NASDAQ: ALIM) after the company received notice from the FDA that approval of Iluvien would be delayed. In the report, Oppenheimer writes "On 12/23, ALIM received an FDA complete response letter (CRL), delaying approval of Iluvien for...

Citigroup has lowered the price target on Alimera Sciences (NASDAS: ALIM) from $15 to $12.

Rodman & Renshaw has initiated coverage on the following companies: Alimera Sciences (NASDAQ: ALIM) Market Outperform, $13 PT Puda Coal (AMEX: PUDA) Market Outperform, $16 PT